SpaceX Hires Natural Gas Trader to Meet Growing Energy Needs 
Welspun Corp Shares Hit Record High on $1.8 Billion U.S. Order 
REPAY Stock Rises After Visa Platform Connect Collaboration 
TikTok, DOJ Reach $400 Million Children’s Privacy Settlement 
Samsung Shares Rise on $72 Billion Shareholder Return Plan 
SK Hynix Shares Surge on Record $28.6 Billion Buyback 
Anthropic IPO Could Challenge SpaceX’s Record $86 Billion Offering 
Barclays Downgrades Renault as Cost Savings Challenges Grow 
Baidu Shares Sink to One-Year Low as Ad Weakness Overshadows AI Growth 
Unitree Robotics Shares Soar Over 600% in Shanghai Market Debut 
Goldman Sachs Names 9 Top Japanese Semiconductor and Electronics Stocks 
SEC Sues Former Tricolor Executives Over $1.9 Billion Investor Fraud Scheme 
Moody’s Affirms NVIDIA Aa1 Rating as AI Data Center Guarantees Reach $105 Billion 
Moody’s Upgrades Vodafone Hybrid Debt Ratings to Baa3 
Toyota, Honda Shares Rise on Possible U.S.-Canada Auto Tariff Cut 
OpenAI Revenue Rises 18% in Q2 as Losses Widen and Anthropic Surges Ahead 
Coty Revenue Beats Estimates as Beauty Demand Holds Firm 
Add as a preferred source on Google
MENLO PARK, Calif., May 08, 2018 -- Corium International, Inc. (NASDAQ:CORI) today announced that it will report financial results for the second quarter ended March 31, 2018 on Monday, May 14, 2018 after the close of the U.S. financial markets. Corium will host a conference call and live audio webcast at 5:00 p.m. Eastern time, 2:00 p.m. Pacific time to discuss its financial results and report on recent progress.
Conference Call and Webcast Details
Investors and analysts can access the call toll-free by dialing (844) 831-3024 (United States) or +1 (315) 625-6887 (international). The conference ID# is 7690614. The conference call will also be available via a live audio webcast which may be accessed here, or by visiting the Investors section of Corium's website at http://ir.coriumgroup.com/events.cfm. The webcast will be archived on the Corium website for two weeks following the presentation.
About Corium
Corium International, Inc. is a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty pharmaceutical products that leverage the company's broad experience with advanced transdermal and transmucosal delivery systems. Corium has multiple proprietary programs in preclinical and clinical development, focusing primarily on the treatment of neurological disorders, with lead programs in Alzheimer's disease. Corium has developed and is the sole commercial manufacturer of seven prescription drug and consumer products with partners Mayne Pharma and Procter & Gamble. The company has two proprietary transdermal platforms: Corplex™ for small molecules and MicroCor®, a biodegradable microstructure technology for small molecules and biologics, including vaccines, peptides and proteins. In addition to its proprietary Alzheimer's program, the company's late-stage pipeline includes a contraceptive patch co-developed with Agile Therapeutics and additional transdermal products that are being developed with other partners. For further information, please visit www.coriumintl.com.
Corplex™ and MicroCor® are registered trademarks of Corium International, Inc.
Investor and Media Contact:
SMP Communications
Susan Pietropaolo
[email protected]
(201) 923-2049
Source: Corium
